Kling Bio, an innovative biotech company based in Amsterdam, has announced a significant collaboration and license option agreement with Sanofi, a global pharmaceutical leader. This strategic partnership is focused on accelerating the discovery of neutralizing antibodies for critical human viral pathogens.

The core of this collaboration lies in Kling Bio's proprietary Kling-Select platform. This advanced technology is a clinically and commercially validated B cell immortalization and screening system. It's designed to rapidly identify novel antibodies and conserved viral epitopes directly from patient-derived B cells. What makes Kling-Select particularly effective is its "function-first" screening workflow, which excels at uncovering rare and highly effective immune targets that are often missed by traditional methods. This approach has already shown success in identifying validated antibody candidates against viruses like RSV, COVID-19, and influenza, highlighting its broad applicability and scientific impact.

The primary objective of this joint effort is to identify and characterize monoclonal antibodies with potent neutralizing activity against a specific, clinically relevant human viral pathogen. The insights gained from this discovery process are expected to be instrumental in developing next-generation antiviral therapeutics and informing the design of more efficacious vaccine candidates.

Michael Koslowski, Kling Bio's CEO, emphasized that this collaboration with Sanofi underscores the immense potential of the Kling-Select platform to address global health challenges by enabling the discovery of first-in-class, human-derived antibodies. By combining Kling Bio's expertise in providing a powerful "window into the human immune response" with Sanofi's extensive leadership in vaccine development, this partnership is poised to advance the next generation of therapeutics and vaccines, ultimately aiming to transform disease prevention and treatment.